Nivolumab Successfully Treats Relapsed/Refractory Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis

The use of nivolumab as a monotherapy in patients with Epstein-Barr virus (EBV)-associated hemophagocytic lymphohistiocytosis (EBV-HLH) was examined in a study. Among seven patients with EBV-HLH who received nivolumab, six responded to it; after a median follow-up of 16 months, five achieved and remained in clinical complete remission. Four patients had complete eradication of both plasma and cellular EBV-DNAs. The researchers suggested that nivolumab could restore a defective anti-EBV response.

Read More